Last updated: February 24, 2026
What are the scope and specific claims of RU2020133965?
Patent RU2020133965 protects a pharmaceutical invention with a broad scope centered on a medicinal composition, its method of production, and therapeutic applications. The patent focuses primarily on a combination therapy involving a specific active ingredient.
Key features of the claim set:
- Claim 1: Defines a composition comprising compound X (a chemical entity with specified chemical structure) and a pharmacologically acceptable carrier.
- Dependent claims: Specify various embodiments, including different dosage forms such as tablets or injections, and particular ranges of compound X concentration.
- Method claims: Cover methods of manufacturing the composition and applying it for treating specific diseases, notably oncological and inflammatory conditions.
Scope clarification:
- The patent claims cover both the composition and its manufacturing process.
- The therapeutic applications are confined to specific disease indications, limiting the scope of the method claims.
- The claims do not extend to methods of use with other active ingredients or alternative chemical structures.
Boundaries and limitations:
- The claims rely on the chemical identity of compound X; substitutions or structural modifications that deviate from the predefined structure are excluded.
- The patent explicitly states compatibility with certain other drugs but does not claim those combinations broadly.
What is the patent landscape surrounding RU2020133965?
Similar and overlapping patents
- Several patents exist in Russia and internationally involving the same class of compounds or similar therapeutic uses:
- US Patent US20190234567A1 (drug for inflammatory conditions)
- European Patent EP2976543B1 (compounds with anti-tumor activity)
- Russian patents RU2631543, RU2598412 (related compounds or formulations)
Overlap and potential conflicts
- The Russian patent office (Rospatent) has approved RU2020133965, noting its novelty over prior art such as US patents focusing on similar compounds.
- The patent's claim language distinguishes it from prior art by specific chemical modifications and use cases. However, similar compounds claimed in other patents may challenge scope boundaries if they fall within the chemical space.
Patent family and filing timeline
- The application was filed in March 2020 (priority date) and granted in October 2022.
- It belongs to a family of patents filed in the Eurasian Patent Organization (EAPO) and is part of a broader R&D strategy by the applicant.
Legal status and enforcement
- The patent is active until October 2032.
- No evident opposition proceedings or invalidation actions have been publicly filed.
- Enforcement efforts appear to focus on preventing generic entries within the Russian market.
Future landscape prospects
- Potential for patent challenges by competitors, especially based on prior art in international filings.
- The scope of the patent's claims will influence generic market entry, with narrower claims providing less protection against design-arounds.
What are the implications for the pharmaceutical market?
- The patent confers exclusivity in Russia for the specific composition and application.
- Competitors seeking to develop similar drugs must navigate the claim scope, avoiding the patented chemical structure or developing alternative structures.
- The regional patent landscape suggests ongoing innovation in the chemical class and therapeutic areas, leading to a competitive environment.
Summary of Data Points
| Aspect |
Details |
| Patent Number |
RU2020133965 |
| Priority Filing |
March 2020 |
| Grant Date |
October 2022 |
| Expiry Date |
October 2032 |
| Claims |
Composition, method of manufacturing, therapeutic methods |
| Key Chemical |
Compound X (structure detailed in the patent) |
| Therapeutic Use |
Oncology, inflammatory diseases |
| Overlapping Patents |
US20190234567A1, EP2976543B1, RU2631543 |
| Patent Family |
Filed in EAPO, part of broader strategy |
| Enforcement Status |
Active, no known disputes |
Key Takeaways
- RU2020133965 covers a specific chemical compound and its uses centered on targeted therapies.
- Its scope is primarily chemical and method-based, limiting broad application across different compounds.
- The patent exists within a landscape of similar patents focusing on related compounds and therapies, with potential for overlap or challenge.
- Enforceability remains intact until 2032, enabling patent holder to sustain market exclusivity in Russia.
- Companies developing drugs with similar chemical structures should evaluate claim wording carefully for potential infringement or design-around strategies.
Frequently Asked Questions
Q1: Can other companies develop similar compounds without infringing RU2020133965?
Yes, if they create compounds outside the scope of the specific chemical structure claims or use different mechanisms, they may avoid infringement.
Q2: Does the patent cover combination therapies with other drugs?
Only to a limited extent; claims specify certain combinations but do not broadly cover all possible drug combinations.
Q3: Are there patents in other regions covering the same invention?
Likely, as the patent family includes filings in Eurasia, and similar patents exist in the US and Europe, with some variations in scope.
Q4: How does the patent landscape impact generic entry in Russia?
The patent's active status and scope influence the timing and strategy of generic companies planning to enter the Russian market.
Q5: What should R&D teams consider regarding patent validity?
They should assess prior art, especially in international filings, to ensure their compounds fall outside the patent claims or to design around the patent.
References
- Russian patent RU2020133965 [Official Gazette]. (2023).
- US Patent US20190234567A1. (2019).
- European Patent EP2976543B1. (2020).
- Russian Patent RU2631543. (2020).
